Lifecare ASA

Share Issue/Capital Change • Jul 5, 2024

LIFECARE ASA: SHARE CAPITAL INCREASE

Reference is made to the stock exchange announcement published by Lifecare ASA ("Lifecare" or the "Company") on 14 June 2024 regarding the final results of the partially underwritten rights issue of new shares in the Company (the "Rights Issue").

The share capital increase pertaining to the issuance of 1,377,572 new shares to certain bottom underwriters in the Rights Issue has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 78,112,907.60 divided on 195,282,269 shares, each with a par value of NOK 0.40.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-07-05 10:07 CEST.